EverPrime review

EverPrime's lowest medication headline is not the number I would use to set a treatment budget. I would start with the standard price, then ask whether membership lowers the complete bill after the separate subscription and any prepayment. This review uses EverPrime's public pages checked in October 2026; it is a pricing and terms assessment, not a report of personal treatment.

Start with the standard price

The semaglutide selector advertises standard rates of $249, $237, $224 and $214 per month for its one-, three-, six- and twelve-month choices. Member medication figures are $150, $138, $125 and $115. The $115 headline therefore belongs to a longer member plan; it does not describe a stand-alone monthly purchase.¹

Tirzepatide has a separate ladder: standard figures of $329, $313, $296 and $280, versus member medication figures of $230, $214, $197 and $180. I would compare the same plan length and prescribed product on both sides. The smaller figure alone cannot establish which arrangement costs less.²

Both product pages describe delivery every four weeks. That is a shipment schedule, and I would not automatically turn it into either calendar-month billing or thirteen annual charges. Ask for the actual debit dates, total prepaid charge and number of shipments. With the advertised $99 Core membership, the one-month member labels add up to $249 for semaglutide ($150 + $99) and $329 for tirzepatide ($230 + $99), matching the standard labels before any other charges. That arithmetic does not resolve the upfront term or debit schedule.¹²

Membership needs its own calculation

The membership page advertises Core at $99 per month and Peak at $199 per month, separately from medication. More concerning is its billing FAQ: it says membership is paid upfront, then gives an example pairing a three-month medication plan with a twelve-month membership charge. I would not silently correct that example or assume three monthly fees. Confirm the membership term and amount due before paying.³

That same page says membership is optional. Its cancellation FAQ describes prepaid payments as nonrefundable, benefits continuing through the prepaid term, and later medication renewals returning to nonmember pricing after cancellation. Stopping renewal and receiving money back are different outcomes.³

Who provides the care?

EverPrime's terms identify the operator as Enhance.MD, LLC, with care supplied through Enhance Wellness, PC, EnhanceMD CA, PC and iThriveMD, PC. They distinguish the platform from the independent licensed professionals responsible for treatment. Our Enhance MD review remains a separate assessment of that offer, not an unrelated clinical alternative. Shared ownership does not establish identical prices or service terms.⁴

The homepage names Dr. Erik Stark as medical director. I would still ask who will evaluate my own case; a leadership biography does not identify every treating clinician.⁷ The FAQ says availability depends on treatment and state, with eligibility confirmed during onboarding. It does not establish nationwide coverage. It also says dispensing pharmacies vary by treatment and location, so ask for the actual pharmacy before accepting a prescription.⁵

Cancellation, delivery and my verdict

The shipping policy asks for contact at least 24 hours before the next billing date to skip or cancel an upcoming shipment. It also says preparation at the pharmacy ends cancellation/refund eligibility, while medical ineligibility receives a full refund. Included two-day shipping starts after dispatch; review and preparation take additional time. Report damaged or incorrect deliveries within 48 hours.⁶

My view: EverPrime warrants a written quote before a long commitment. I would want medication, membership, debit dates and cancellation deadlines on one page. Its compounded GLP-1 products are not FDA-approved; a prescription and pharmacy fulfillment do not make them approved equivalents to branded drugs.⁸ Use our provider selection guide to compare the complete obligation and teaser-rate guide to separate a headline from an ongoing bill.